Pabau Engage inbox

Pabau Engage is here: every patient conversation in one inbox.

Learn more
Book a demo Book a demo
☰
Men's Health

TRT consent form: Free template with a signed monitoring schedule

Free PDF 6 pages, print-ready Clinician-reviewed


A TRT consent form records the FDA-labeled risks discussed, the hematocrit, PSA and testosterone checks agreed, fertility and Schedule III acknowledgments, and both signatures. This free template is print-ready and written for men’s TRT. Have your medical director and legal counsel review it before first use.

The form is built around the signed monitoring schedule. The prescriber fills in dated hematocrit, PSA and testosterone checks at the intervals the product label and the Endocrine Society guideline set. The patient initials each acknowledgment and signs up to those dates before the first dose.

The PDF runs to six pages, with a cover page for the practice and five pages for the patient. What follows covers the label-sourced monitoring schedule, route addenda and telehealth rules for a Schedule III drug.

Template details
Template type
Consent form
Format
Printable PDF, 6 pages
Best for
Men's Health
Free download

Download your free TRT consent form

A nine-section men’s TRT consent form with patient and treatment details, FDA-labeled risks to initial, and a contraindication screen. The form also holds hematocrit, PSA and fertility acknowledgments, the signed monitoring schedule, a Schedule III and telehealth statement, and signature lines.

What’s inside
  • Practice cover page with review note, build notes, section index and dated sources
  • Patient, prescriber and treatment details, two morning testosterone results and label status
  • FDA-label risk table with the label section, revision date and initials per risk
  • Contraindication screen with FDA yes or no lines and separate Endocrine Society cautions
  • Hematocrit, PSA and fertility initials, plus the signed monitoring schedule with due dates
  • Schedule III and telehealth statement, decline option, and patient and prescriber signatures
PDF · 6 pages · 252 KB No sign-up needed Updated November 2026
Generate it. Send it. File it automatically.

Turn this template into a Smart Form

Start from scratch, or upload this PDF or any form you already use, and Pabau's AI Form rebuilds it with tick boxes, text fields and a signature. Attach it to the treatment once, and every patient gets it on time.

  • Generate with AI from a PDF, Word file or photo
  • Precare before the visit, aftercare after checkout
  • Signed forms saved to the patient record

Why practices run their forms on Pabau

Bring your forms across fast

AI Form rebuilds the consent, history and aftercare forms you already use. You review each one, then publish.

Save hours every week

Patients complete forms on their phone before they arrive, so the front desk stops retyping paper.

Stay audit-ready

Every signed form is versioned and attached to the treatment record, ready when you need it.

Ask patients once

Set how long a consent stays valid. Returning patients skip forms they have already signed.

Supports HIPAA and GDPR compliance AES-256 encryption 4.8 on G2 4.7 on Capterra Trusted by 4,000+ practices worldwide

Key takeaways

Key takeaways

A TRT consent form covers the labeled indication, FDA-label risks, a contraindication screen, monitoring, Schedule III status and two signatures.

The signed monitoring schedule puts dated checks on the form, starting with hematocrit before treatment, at 3 to 6 months and then annually.

No FDA testosterone label sets a numeric hematocrit cutoff, so the form says treatment may pause if hematocrit rises.

The AndroGel 1.62% and Xyosted labels say the impact on fertility may be irreversible, so the form records a sperm-banking discussion.

Testosterone is a Schedule III controlled substance, and the DEA telemedicine flexibility for prescribing it currently runs through December 31, 2026.

Found our content helpful?

A testosterone replacement therapy consent form covers patient and treatment details, the labeled diagnosis, FDA-label risks, contraindications, monitoring, Schedule III status, responsibilities and signatures. Each clinical line comes from the product’s prescribing information. The AndroGel 1.62% prescribing information, revised July 2025, holds the form’s spine.

That label sets hematocrit checks and prostate evaluation before and during treatment, and it warns that fertility effects may be irreversible.

We often see men’s health practices start from a testosterone consent form written for women or for gender-affirming care. Those are the forms that rank, and they leave out PSA, a hematocrit schedule and Schedule III status. The downloadable PDF has nine sections, and each one closes a part of that list.

  1. Patient, prescriber and treatment details: Name, date of birth, MRN, product, route, dose, frequency and start date.
  2. Diagnosis and FDA approval status: The labeled indication, two low morning testosterone results and the age-related limitation.
  3. Risks from the FDA prescribing information: Each labeled risk with its source, revision date and a patient initial.
  4. Contraindication screen: FDA contraindications as yes or no lines, plus Endocrine Society cautions marked as non-FDA.
  5. Hematocrit, PSA and fertility acknowledgments: Initial-each-line statements and a sperm-banking discussion line.
  6. The signed monitoring schedule: Each check with its sourced interval, a date due and a date done.
  7. Controlled substance and telehealth statement: Schedule III status, a no-sharing promise and the dated DEA telemedicine position.
  8. Responsibilities, withdrawal and the decline option: Patient duties, the right to stop, alternatives and a begin or decline line.
  9. Signatures: Patient and prescriber signatures with dates, an optional witness line and the form version.

The contraindication screen also asks for the patient’s current prostate and BPH medicines. A prostate medication list helps staff record those drugs by class.

Most lines in the PDF’s risk table cite the AndroGel 1.62% label, revised July 2025 and checked November 16, 2026. The AndroGel 1.62% label warns of raised hematocrit, blood pressure increases, worsening BPH, prostate cancer risk, blood clots and worse sleep apnea. The label also covers edema, gynecomastia, lipid and liver effects, and abuse and dependence.

The Xyosted label, also revised July 2025, adds a warning on depression and suicidality. Both labels say the impact on fertility may be irreversible, and AndroGel 1.62% carries a boxed warning for secondary exposure. FDA’s February 28, 2025 class-wide labeling change removed boxed warning language on adverse cardiovascular outcomes.

What monitoring schedule does the patient sign up to?

The patient agrees to baseline checks, a hematocrit recheck at 3 to 6 months, a PSA review at 3 to 12 months and annual hematocrit.

In the PDF, the signed monitoring schedule lists each check with its sourced interval, a due date and a done date. The prescriber fills in the due dates on the day of consent, counting from the start date. Where a label says only “periodically”, the form says so and the prescriber sets the date.

Those dates come from the product’s own label, because the labels differ. The AndroGel 1.62% label sets hematocrit 3 to 6 months after starting, then annually. The Xyosted label asks for hematocrit about every 3 months. The Depo-Testosterone label says hemoglobin and hematocrit should be checked periodically.

No FDA label sets a numeric hematocrit cutoff. The AndroGel 1.62% and Xyosted labels say to stop when hematocrit becomes elevated and restart once it falls to an acceptable level. Xyosted adds a permanent stop after a second rise. A form that cites an “FDA 54% limit” quotes a figure the labels do not contain.

CheckWhenSource (checked November 16, 2026)
HematocritBefore starting, at 3 to 6 months, then annuallyAndroGel 1.62% label §5.2, revised 07/2025
HematocritAbout every 3 monthsXyosted label §5.1, revised 07/2025
Hemoglobin and hematocritPeriodicallyDepo-Testosterone label, revised 10/2025
Morning total testosteroneOn two separate days before startingAndroGel 1.62% §2; Xyosted §2.1
Trough testosterone6 weeks after starting and after a dose change, then periodicallyXyosted §2.2
Prostate evaluationBefore starting and during treatmentAndroGel 1.62% §5.4; Xyosted §5.3
Prostate cancer risk (PSA)Before starting and 3 to 12 months afterEndocrine Society 2018, not FDA
Blood pressurePeriodicallyAndroGel 1.62% §5.5; Xyosted §5.4
PSA, lipids and liver testsPeriodicallyAndroGel 1.62% Highlights

PSA timing comes from the Endocrine Society’s 2018 guideline, which is not an FDA requirement. The guideline advises assessing prostate cancer risk before starting and 3 to 12 months after. It also advises urology referral for any of these findings:

  • A confirmed PSA rise of more than 1.4 ng/mL above baseline within the first 12 months.
  • A confirmed PSA above 4.0 ng/mL.
  • A prostate abnormality found on digital rectal examination.

A restart after a hematocrit stop is a new decision, so the patient re-signs the schedule with fresh dates. On Xyosted, that signature also records that a second rise ends treatment with the product.

For results between visits, the monthly hormone cycle template is a separate tracking sheet. The consent form records the agreement, and the tracking sheet records the numbers.

Testosterone injection consent needs an addendum when the product label adds route-specific lines, such as Xyosted’s 3-month hematocrit checks, sesame oil allergy and suicidality warning.

One core form covers every route, and each route gets a one-page addendum. Shared risks stay in one place, and the product-specific lines sit next to the product.

  • Xyosted (testosterone enanthate autoinjector): Hematocrit about every 3 months, with a permanent stop after a second rise. The addendum adds the sesame oil allergy question and the depression and suicidality warning from section 5.15.
  • Depo-Testosterone (testosterone cypionate): Hemoglobin and hematocrit checked periodically, plus the hypersensitivity and serious heart, liver or kidney disease contraindications.
  • Gel (AndroGel 1.62%): The secondary exposure boxed warning. Children and women avoid unwashed or unclothed application sites, and the gel stays flammable until it dries.
  • Pellets: Pellet insertion is a procedure, so pellets need a consent form of their own.

Re-consent when any of these happens:

  • The route or the product changes.
  • Treatment restarts after a hematocrit stop.
  • The product label changes. FDA’s June 2026 request on the age-related limitation had not reached the labels checked November 16, 2026.

The AndroGel 1.62% label, revised July 2025, and the Depo-Testosterone label, revised October 2025, say safety and efficacy in age-related hypogonadism have not been established.

FDA requested removal of that limitation in June 2026, per its Testosterone Information page, current as of June 23, 2026. A request is not an approval, and the labels checked November 16, 2026 still carry it.

Women and menopause patients need a different form. The BHRT consent form covers bioidentical hormone therapy with its own intake questions.

Informed consent for testosterone therapy by telehealth adds a dated statement of the DEA’s telemedicine rules, because testosterone is a Schedule III controlled substance.

Federal law lists testosterone as item (84) under anabolic steroids in 21 CFR 1308.13(f), checked November 16, 2026. The PDF’s controlled substance statement has the patient agree to use testosterone only as prescribed and never share it.

The fourth temporary extension, published December 31, 2025, lets practitioners prescribe Schedule II to V medicines by telemedicine without a prior in-person evaluation. That extension runs from January 1 through December 31, 2026.

The DEA’s Special Registration rule is still a proposed rule from January 17, 2025. No final rule or fifth extension had been published when we checked on November 16, 2026.

Three points follow for the form:

  • The patient signs the consent before the video visit, so the prescriber can review it during the call.
  • The form records that the visit was audio-video, with the date the practice last checked the rule.
  • Telehealth prescribing rules also vary by state, so the medical director confirms them for each state the practice serves.

Pabau, the practice management platform we build, sends the TRT consent form before the visit and saves the signed copy to the patient record. The workflow takes three steps.

  1. Build the nine sections once as a Pabau form, with a field for each line the patient initials.
  2. Send it with the intake forms before the visit. Pabau GO, our iOS app for practitioners, supports care-pathway forms and consents and shows pre-appointment steps as a checklist.
  3. The completed form lands in the patient record rather than a folder of PDFs, so the prescriber reviews it beside the patient’s notes.

The diagram follows one patient from the signed form to the first annual hematocrit.

Flow diagram of a TRT consent form workflow: form sent before the visit, signed digitally with initials, saved to the patient record, then baseline hematocrit, morning testosterone on two separate days and prostate evaluation; hematocrit recheck at 3 to 6 months and annually (AndroGel 1.62% label); prostate cancer risk reassessed at 3 to 12 months (Endocrine Society 2018, not FDA).
The consent form starts the signed monitoring schedule, so every recheck date exists before the first dose. Intervals come from the AndroGel 1.62% and Xyosted labels and the Endocrine Society 2018 guideline.

For a wider launch, our guide on how to start a TRT clinic sets out the other steps in order.

A paper TRT consent form records consent, but it cannot chase signatures, recall patients for labs, pull in results or show trends. Pabau runs booking, charting, consent forms, payments and memberships for practices that offer aesthetics, hormone therapy, weight loss and longevity care in one system. Our ranking of the best TRT clinic software scores eight platforms on labs, recalls and prescribing.

Paper or PDF limitHow the practice handles it in Pabau
Unsigned forms get chased by phone on the morning of the visit.The form goes out before the visit, and Pabau GO shows the team which pre-appointment steps are still open.
The signed PDF sits in a folder, apart from the chart.The completed form lands in the patient record and does not sit as a PDF.
Monitoring dates live in one prescriber’s calendar.Recall Workflows, with 90-day and 6-month templates, send SMS, email or WhatsApp and skip patients who already have a booking. SMS uses usage-based credits.
Lab results arrive as PDFs to file by hand.Practices can switch on Labs. Quest results import automatically, Labcorp results sync back from Labcorp Link, and a biomarker trend chart sits on the record.
Blood pressure and weight are written on paper.The Measures tab charts vitals and weight over time, beside lab trends.
The patient calls the front desk to hear results.The patient portal shows the lab results the practice shares, with trends. The practice switches each portal section on or off.

TRT practices run Pabau as men’s health clinic software, so the consent form, the recalls and the lab results share one patient record. Every Pabau plan includes the core features, and add-ons enhance the experience. Pabau is rated 4.7 on G2 and 4.7 on Capterra.

Turn signed consent into booked lab rechecks

Pabau sends the TRT consent form before the visit and saves it to the patient record. Recall Workflows then bring patients back for the hematocrit and PSA checks they signed up to.

Pabau practice management dashboard

Conclusion

A TRT consent form is only as good as the monitoring that follows it. The signature shows the patient understood the hematocrit, PSA and fertility risks. The protection comes from the rechecks happening on the dates the form set.

So treat the form as the first page of a schedule. Record the date you checked the label, and re-sign after any product change or restart. Review the wording when FDA’s June 2026 request reaches the labels, and again before the DEA flexibility ends on December 31, 2026.

Book a demo to see how Pabau sends the consent form before the visit and brings each TRT patient back for their signed checks.

Continue your research

Continue your research

Setting up a new TRT service? How to start a TRT clinic walks through launching a testosterone practice step by step.

Need to log hormone results between visits? Male monthly hormone cycle template is a tracking sheet kept apart from the consent form.

Treating menopause or BHRT patients too? BHRT consent form pairs a hormone therapy consent with an intake form.

Tracking estradiol alongside testosterone? Male estrogen levels template records estrogen results for male patients.

Offering pellets as well? Hormone pellet insertion covers the procedure a pellet consent describes.

Frequently asked questions

Is testosterone a controlled substance?

Yes. Federal law lists testosterone as a Schedule III anabolic steroid in 21 CFR 1308.13(f), checked November 16, 2026. A testosterone consent form should state that status, and the patient agrees to use it only as prescribed and never share it.

How often should a TRT patient re-sign consent?

A TRT patient re-signs when the product or route changes, when treatment restarts after a hematocrit stop, and when the label changes. A switch from gel to injection needs the testosterone injection consent addendum signed first. Your medical director can also set an annual re-sign date in practice policy.

Does the FDA set a hematocrit cutoff for stopping testosterone?

No. The AndroGel 1.62%, Xyosted and Depo-Testosterone labels give no numeric hematocrit cutoff. The AndroGel 1.62% and Xyosted labels say to stop when hematocrit becomes elevated and restart once it falls to an acceptable level. Xyosted adds a permanent stop after a second rise.

Can one consent form cover testosterone injections, gels and pellets?

One core form can cover injections and gels, with a short addendum for each route. The gel addendum carries the secondary exposure boxed warning, and the Xyosted addendum adds the sesame oil allergy question. Pellets need their own consent, because insertion is a procedure.

Is testosterone approved for age-related low testosterone?

Not under current labeling. The AndroGel 1.62% and Depo-Testosterone labels say safety and efficacy in age-related hypogonadism have not been established. FDA requested removal of that limitation in June 2026, but the labels checked November 16, 2026 still carry it.

Found our content helpful?
Avatar photo
Maja Popovska
Content Writer

Maja is a Senior Content Writer at Pabau, where she covers everything from practice management and compliance to medical aesthetics and patient experience. Off the clock: binging true crime docuseries, baking and dreaming about travel.
×